Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. (1st April 2020) - Cogle, Christopher R.; Collins, Bradley; Turner, Daniel; Pettiford, Leslie C.; Bossé, Raphael; Hawkins, Kimberly E.; Beachamp, Zackary; Wise, Elizabeth; Cline, Christina; May, William S.; Moreb, Jan S.; Hsu, Jack; et al.